Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Company Deals

Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million

Fineline Cube Jul 8, 2026
Company Deals

MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001

Fineline Cube Jul 8, 2026
Company Deals

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Fineline Cube Jul 8, 2026
Policy / Regulatory

China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List

Fineline Cube Jul 8, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Fineline Cube Jul 8, 2026
Company Drug

Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus

Fineline Cube Jul 8, 2026
Company Drug Legal / IP

Hainan Shuangcheng Files Paragraph IV Patent Declaration for Paclitaxel, Albumin-Bound

Fineline Cube Dec 29, 2022

China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has announced a Paragraph IV patent declaration...

Company Drug

Grand Pharma’s COVID-19 Therapy GS221 Shows Promising Safety Profile

Fineline Cube Dec 29, 2022

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its clinical study for the...

Company Drug

Fosun Pharma Launches Online Registration for BioNTech COVID-19 Vaccine in Hong Kong

Fineline Cube Dec 29, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced a new initiative...

Company Drug

Immunotech Biopharm’s CAR-T-19-D2 IND Filing Accepted by NMPA

Fineline Cube Dec 29, 2022

China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced that...

Company Medical Device

Acotec Scientific Holdings Receives NMPA Approvals for YAN and P-Conic Balloon

Fineline Cube Dec 29, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving market approvals from the National...

Company Drug

CanSino Biologics Updates Data from COVID-19 Vaccine Clinical Studies

Fineline Cube Dec 29, 2022

China-based CanSino Biologics (HKG: 6185) has provided data updates from three clinical studies for its...

Company Deals

Fortune Care Raises Over RMB 100 Million in Series C+ Financing Round

Fineline Cube Dec 29, 2022

China-based household healthcare and nursing brand Fortune Care reportedly raised over RMB 100 million (USD...

Company Deals

Guangzhou Mygene Raises ‘Hundreds of Millions’ in Series C Financing Led by Efund Capital

Fineline Cube Dec 29, 2022

China-based molecular diagnostic product developer Guangzhou Mygene Medical Technology Co., Ltd reportedly raised “hundreds of...

Company

WuXi Biologics Receives First GMP Certificate from Ireland HPRA

Fineline Cube Dec 28, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced receiving...

R&D

CARsgen Develops New CAR-T Technique to Enhance Anti-Tumor Activity

Fineline Cube Dec 28, 2022

China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced...

Company Drug

SciClone Pharmaceuticals’ Vaborem IND Filing Accepted by NMPA

Fineline Cube Dec 28, 2022

SciClone Pharmaceuticals Inc (HKG: 6600) has announced that an Investigational New Drug (IND) filing for...

Company Drug

Luye Pharma’s Paliperidone Palmitate Accepted for NMPA Review

Fineline Cube Dec 28, 2022

China-based Luye Pharma Group (HKG: 2186) has announced that the market filing for its paliperidone...

Policy / Regulatory

China Downgrades COVID-19 from Class A to Class B Infectious Disease

Fineline Cube Dec 28, 2022

The National Health Commission (NHC) has issued a notice downgrading COVID-19 from a Class A...

Company Deals

Carrier Biomed Raises ‘Tens of Millions’ in Series A+ Financing Round

Fineline Cube Dec 28, 2022

Carrier Biomed (Soohow) Co., Ltd, an exosome technology developer based in Suzhou, has reportedly raised...

Company

Everest Medicines Launches First Phase of Global mRNA Vaccine Manufacturing Site

Fineline Cube Dec 28, 2022

China-based Everest Medicines (HKG: 1952) has announced the initiation of the operation of the first...

Company Drug

InnoCare Pharma Receives Hong Kong Approval for Tafasitamab in DLBCL

Fineline Cube Dec 28, 2022

China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the...

Company Deals

LeadArt Biotechnologies Raises USD 6 Million in Pre-Series A Round

Fineline Cube Dec 28, 2022

LeadArt Biotechnologies Inc., a chemical proteomics specialist based in Ningbo, has reportedly raised close to...

Company Drug

Simcere Receives NMPA Clearance for SIM0237 Clinical Study

Fineline Cube Dec 28, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced receiving clearance from the National Medical Products...

Company Drug

CStone Pharmaceuticals Publishes Ayvakit Study Results on Oncologist Website

Fineline Cube Dec 28, 2022

China-based CStone Pharmaceuticals (HKG: 2616) has published the results of the China-based bridging NAVIGATOR study...

Company Deals

Biosion Completes Series B Financing Round Led by Guangfa Xinde Investment

Fineline Cube Dec 28, 2022

Biosion, a global, clinical-stage biotech committed to developing antibody-based therapies targeting immune and oncologic diseases,...

Posts pagination

1 … 607 608 609 … 692

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors
  • AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy
  • OTR Therapeutics Partners with LG Chem to Accelerate Early-Stage Oncology Programs with China-Global Development Model
  • Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus
  • Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Others

AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy

Others

OTR Therapeutics Partners with LG Chem to Accelerate Early-Stage Oncology Programs with China-Global Development Model

Company Drug

Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.